These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29050007)

  • 1. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Takeuchi K; Shimoyama T; Yamamoto T
    Dig Dis; 2018; 36(2):106-112. PubMed ID: 29050007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.
    Otsuka T; Ooi M; Tobimatsu K; Wakahara C; Watanabe D; Adachi S; Yasutomi E; Yamairi H; Ku Y; Yoshida M; Hoshi N; Kodama Y
    Kobe J Med Sci; 2018 Dec; 64(4):E140-E148. PubMed ID: 30728340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
    Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.
    Jia X; Guo R; Hu Z; Liu J; Liu J; Li B; Yang Q; He J
    Medicine (Baltimore); 2020 Oct; 99(44):e22894. PubMed ID: 33126341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis.
    Zhao HN; Jiang M; Sun MJ; Dai C
    Saudi J Gastroenterol; 2021; 27(4):191-200. PubMed ID: 34380865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Tacrolimus and Infliximab in Hospitalized Patients With Ulcerative Colitis.
    Takahashi T; Shiga H; Tarasawa K; Shimoyama Y; Naito T; Moroi R; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00642. PubMed ID: 37753937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis.
    Liu YJ; Fan H; Zhen WW; Yu X; Chen JT; Wang CD
    Medicine (Baltimore); 2018 Aug; 97(32):e11440. PubMed ID: 30095612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Tacrolimus or Infliximab Therapy in Children and Young Adults With Acute Severe Colitis.
    Zimmerman LA; Spaan J; Weinbren N; Manokaran K; Ajithkumar A; Bogursky A; Liu E; Lillehei C; Weil BR; Zalieckas JM; Bousvaros A; Rufo PA
    J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):222-227. PubMed ID: 37477885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
    Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study.
    Minami N; Yoshino T; Matsuura M; Koshikawa Y; Yamada S; Toyonaga T; Madian A; Honzawa Y; Nakase H
    BMJ Open Gastroenterol; 2015; 2(1):e000021. PubMed ID: 26462273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.
    Endo K; Onodera M; Shiga H; Kuroha M; Kimura T; Hiramoto K; Kakuta Y; Kinouchi Y; Shimosegawa T
    Gastroenterol Res Pract; 2016; 2016():3162595. PubMed ID: 26904108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of infliximab and tacrolimus combination therapy in a patient with ulcerative colitis refractory to infliximab dose intensification plus azathioprine.
    Cortes X; Borrás-Blasco J; Fernendez S; Moreno M; Rodríguez J; Molés JR; Casterá E
    Int J Clin Pharmacol Ther; 2016 Feb; 54(2):125-8. PubMed ID: 26754306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study.
    Nasuno M; Miyakawa M; Tanaka H; Motoya S
    Digestion; 2017; 95(1):67-71. PubMed ID: 28052276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients.
    Kitayama M; Akazawa Y; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Nakashima Y; Tabuchi M; Hashiguchi K; Matsushima K; Yamaguchi N; Kondo H; Nakao K; Takeshima F
    Sci Rep; 2020 Jul; 10(1):12546. PubMed ID: 32719413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis.
    Komaki Y; Komaki F; Micic D; Yamada A; Suzuki Y; Sakuraba A
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1143-1151. PubMed ID: 27957761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.